Opportunities for innovation and flexibility in mRNA and LNP manufacturing

From global vaccines to personalized cancer therapies, mRNA is being considered for a variety of clinical applications, creating varying requirements for production scale and dosage. To meet these diverse needs, flexibility in the manufacturing process is critical, as drug developers must determine how to efficiently deliver high yields of quality mRNA while also balancing logistical and financial goals.

Partnering with an adaptable and collaborative CDMO can be essential to navigating industry challenges and finding the best solution to bring your unique mRNA vaccine or therapeutic to market. In our upcoming webinar, we will explore different options within a standard mRNA/LNP manufacturing workflow and highlight Thermo Fisher Scientific innovations to support varying production strategies and enhance your process, including:

• Synthetic DNA vs. plasmid DNA for template generation
• Use of fit-for-purpose plasmid DNA-backbones
• Leveraging DOE principles for mRNA and LNP process development
• Scale up optimization in mRNA and LNP manufacturing
• Comprehensive analytical characterization

You will learn from this webinar:

• Trends and innovations in mRNA/LNP manufacturing workflow
• Application of DOE principles to optimize your production strategy
• Benefits of all-in-one drug substance and drug product CDMO solutions for mRNA